Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 50 mg/ml - oral liquid, suspension - excipient ingredients: benzoic acid; glycerol; citric acid; sodium chloride; purified water; sodium citrate dihydrate; propylene glycol; xylitol; sodium cyclamate; microcrystalline cellulose; carmellose sodium; flavour - treatment of chronic cholestatic liver diseases.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

haleon uk ltd - nicotine - medicated chewing-gum - 2mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

haleon uk ltd - nicotine - medicated chewing-gum - 4mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

omega pharma ltd - thyme; marshmallow root - oral suspension - 8mg/1ml ; 55.33mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - calcium carbonate - oral tablet - 250mg

Australia - English - Department of Health (Therapeutic Goods Administration)

dr falk pharma australia pty ltd - ursodeoxycholic acid, quantity: 50 mg/ml - oral liquid, suspension - excipient ingredients: purified water; sodium cyclamate; citric acid; sodium citrate dihydrate; xylitol; sodium chloride; glycerol; propylene glycol; benzoic acid; microcrystalline cellulose; carmellose sodium; flavour - treatment of chronic cholestatic liver diseases.

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - ticagrelor, quantity: 90 mg - tablet, dispersible - excipient ingredients: mannitol; microcrystalline cellulose; crospovidone; xylitol; calcium hydrogen phosphate; sodium stearylfumarate; hyprolose; colloidal anhydrous silica - brilinta, in combination with aspirin, is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) in adult patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]) including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - lamivudine - film coated tablets - lamivudine 150 mg - lamivudine - epivir is indicated as part of antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infected adults and children.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - lamivudine - film coated tablets - lamivudine 300 mg - lamivudine - epivir is indicated as part of antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infected adults and children. 28/10/2018 בקשה לשינוי משטר מינון

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - abacavir as sulfate; lamivudine - film coated tablets - abacavir as sulfate 600 mg; lamivudine 300 mg - kivexa is a fixed-dose combination of two nucleoside analogues (abacavir and lamivudine). it is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.28/10/2018 עדכון התוויה: kivexa is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and, adolescents s of and children weighing at least 25 kg.שינוי משטר מינון:adults, adolescents and children weighing at least 25 kg:the recommended dose of kivexa is one tablet once daily.children under 25 kg: kivexa should not be administered children who weigh less than 25 kg because it is a fixed dose tablet that cannot be dose reduced.paediatric population: the safety and efficacy of kivexa in children weighing less than 25 kg has not been established. currently available data are described in section 4.8, 5.1 and 5.2 but no recommendation on posology can be made.